1. Adaptation of the Th-MYCN Mouse Model of Neuroblastoma for Evaluation of Disseminated Disease.
- Author
-
Rahavi, Seyed M., Aletaha, Maryam, Farrokhi, Ali, Lorentzian, Amanda, Lange, Philipp F., Maxwell, Christopher A., Lim, Chinten James, and Reid, Gregor S. D.
- Subjects
- *
NEUROBLASTOMA , *LABORATORY mice , *ANIMAL disease models , *THERAPEUTICS , *ANIMAL models in research , *BONE marrow - Abstract
High-risk neuroblastoma remains a profound clinical challenge that requires eradication of neuroblastoma cells from a variety of organ sites, including bone marrow, liver, and CNS, to achieve a cure. While preclinical modeling is a powerful tool for the development of novel cancer therapies, the lack of widely available models of metastatic neuroblastoma represents a significant barrier to the development of effective treatment strategies. To address this need, we report a novel luciferase-expressing derivative of the widely used Th-MYCN mouse. While our model recapitulates the non-metastatic neuroblastoma development seen in the parental transgenic strain, transplantation of primary tumor cells from disease-bearing mice enables longitudinal monitoring of neuroblastoma growth at distinct sites in immune-deficient or immune-competent recipients. The transplanted tumors retain GD2 expression through many rounds of serial transplantation and are sensitive to GD2-targeted immune therapy. With more diverse tissue localization than is seen with human cell line-derived xenografts, this novel model for high-risk neuroblastoma could contribute to the optimization of immune-based treatments for this deadly disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF